UroAlert - GU Oncology Weekly

April 09, 2026

Videos

Peer-to-Peer Clinical Conversations

Translational Insights for Cretostimogene Grenadenorepvec for BCG-Naïve Bladder Cancer - Trinity Bivalacqua

Trinity Bivalacqua

Trinity Bivalacqua discusses the translational data from CORE-008 Cohort A, examining cretostimogene grenadenorepvec in high-risk BCG-naive NMIBC with a focus on the five-step versus two-step administration protocol.

Interim PSMAddition Analysis Shows Lutetium PSMA-617 Improves rPFS in mHSPC - Scott Tagawa

Scott Tagawa

Oliver Sartor speaks with Scott Tagawa about the PSMAAddition trial examining lutetium PSMA-617 added to androgen deprivation therapy and androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer.

Beyond the Abstracts

Outcomes of Immune Checkpoint Inhibitor Rechallenge in Advanced Urothelial Carcinoma: Results from a Global Real-World Evidence Study - Beyond the Abstract

Predicting Recurrence After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: Development and Validation of the JIKEI-YAYOI Score - Beyond the Abstract

Conference Coverage

SES AUA 2026: Darolutamide Plus Androgen-Deprivation Therapy in Patients with Metastatic Hormone-Sensitive Prostate Cancer: Efficacy and Safety by Disease Volume in the Phase 3 ARANOTE Study

SES AUA 2026: UGN-102 for Low-Grade Intermediate Risk Non Muscle Invasive Bladder Cancer: 5-Year Long-Term Extension Study Results from the Single-Arm, Phase 2B OPTIMA II Study

EAU 2026: Pre-Cystectomy ctDNA Burden May Identify Patients Who Can Benefit from Upfront Radical Cystectomy

EAU 2026: [89Zr]Zr-girentuximab PET/CT in the Non-invasive Characterization of Indeterminate Renal Lesions: Initial Real-world Clinical Experience

ASCO GU 2026: A Phase II Trial of Cabozantinib in Relapsed Refractory Germ Cell Tumors

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Loss of KDM6A-Mediated Genomic Instability and Metabolic Reprogramming Regulates Response to Therapeutic Perturbations in Bladder Cancer - Beyond the Abstract

Contemporary Microhematuria Evaluation in Veterans: Cancer Detection and Resource Utilization - Beyond the Abstract

Hypoxia-Induced microRNAs confer survival advantage in bladder cancer by fine-tuning oncogenic Pathways.

Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder-sparing Treatment for Muscle-invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial.

Adjuvant Radiotherapy After Cystectomy in Muscle-Invasive Bladder Cancer: Indications, Benefits and Remaining Challenges.

Digital Uromonitor® outperforms quantitative polymerase chain reaction Uromonitor and cytology for non-muscle-invasive bladder cancer surveillance: results from the 'External Validation of Uromonitor as a Biomarker for Optimization of NMIBC Management by

Risk stratification of Ta high-grade non-muscle-invasive bladder cancer: Insights from a multicenter cohort study.

Stage-independent real-time subtype classification and comprehensive biopsy profiling of urothelial carcinomas by the Lund Taxonomy system.

Role of Neoadjuvant Therapy in Histological Variant Urothelial Carcinoma.

Outcomes of Consolidative Surgery Following Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Cancer: A Real-World Experience.

Costs of care and oncologic outcomes associated with blue light cystoscopy in an equal access setting: Results from the BRAVO study.

Impact of a multidisciplinary approach on outcomes in urothelial carcinoma.

Real-World Survival Outcomes and Prognostic Factors in De Novo Stage IV Urothelial Bladder Cancer: A 13-Year Retrospective Cohort Study.

INLEXZO™ (gemcitabine intravesical system) Assigned Permanent Billing Code, Supporting Access for Patients with Certain Bladder Cancers

NCCN 2026 Bladder Cancer Guidelines Adopt IBCG Risk Stratification Model for Intermediate-Risk NMIBC

Active surveillance in low-grade NMIBC - results of an international two-round modified Delphi consensus.

Impact of audit and feedback on transurethral resection of bladder tumour quality: a monocentric post-completion evaluation of the RESECT trial.

Penile & Urethral Cancers

Neoadjuvant and/or adjuvant immune checkpoint inhibitors combined with chemotherapy for locally advanced resectable penile squamous cell carcinoma.

Danish National Penile Cancer Database, DaPeCa-data: characteristics, management, and survival 2000-2025.

Mohs Micrographic Surgery for Penile Squamous Cell Carcinoma: A Systematic Review.

7-Year Data on Penile Carcinoma from the VERSUS Study by d-uo.

Renal Cancer

Cabozantinib in patients with non-locally pretreated brain metastases from renal cell carcinoma: Results of the multicenter phase II trial CABRAMET.

SET1B Drives Sustained HIF activity and Disease Progression in Clear Cell Renal Cell Carcinoma.

Evaluating Nephrectomy Outcomes in Regional Victoria: A Single-Centre Cohort Study.

Concurrent Tissue and Circulating Tumor DNA analysis in Renal Cell Carcinoma: Insights from a Multimodal Database.

Laboratory paraneoplastic syndrome resolution is associated with reduced recurrence and improved survival in non-metastatic renal cell carcinoma.

Outcomes of Complete Responders From First-line Therapy in Metastatic Renal Cell Carcinoma in the Real World: An Analysis From the International Metastatic Renal Cell Carcinoma Database Consortium.

KIM-1 in Advanced Papillary and Clear Cell Renal Cell Carcinoma.

Improving the diagnosis of renal tumours of young people through integrated molecular analysis.

CT-based renal artery caliber change as a potential imaging marker of treatment response in renal cell carcinoma; an exploratory imaging study.

The Effect of Allogenic Blood Transfusion on Oncologic Outcomes in Locally Advanced Kidney Cancer.

Prostate Cancer

Trends and Disparities in the Use of Next-Generation Sequencing in Patients With Cancer in the United States.

Advances in Androgen Deprivation Therapy-Sparing Strategies: Ongoing Studies in Metastatic Castration-Sensitive Prostate Cancer.

Characterization of Clinically Significant Prostate Cancer in the Peripheral Zone Using Rapid B1-Insensitive MR Fingerprinting.

Moderate hypofractionation: long-term toxicity results of prostate bed radiotherapy (FRAME-PROSTATE).

Leveraging Population-Level and Multipayer Claims Data to Estimate Changes in Prostate Cancer Screening at the Small-Area Level.

Mediation analysis of adherence to pelvic floor muscle training and weekly self-monitoring on urinary symptoms in men with localized prostate cancer: A secondary analysis of the Prostate Cancer-Patient Empowerment Program (PC-PEP) randomized controlled tr

Clinical Characteristics and Predictive Factors of Symptomatic Skeletal Events in Patients With Metastatic Castration-Sensitive Prostate Cancer Treated With Denosumab.

Dosimetric comparison of implantable rectal spacers for low-dose-rate prostate brachytherapy.

Cost-effectiveness of PSMA-PET imaging technology in diagnosing and staging of prostate cancer: a systematic review.

The molecular pathology of prostate cancer: an update for practising pathologists.

Optimizing ChatGPT: Applying prompt engineering to frequently asked questions in urologic oncology.

Simulation-Free Adaptive Prostate SBRT on MR-Linac: Technical Feasibility and Clinical Experience.

Survival Outcomes of Cabazitaxel or Subsequent Androgen Receptor Pathway Inhibitor (ARPI) in Post-Docetaxel/ARPI Metastatic Castration-Resistant Prostate Cancer - Beyond the Abstract

Predictive factors for biochemical recurrence after radical prostatectomy in ISUP Grade Group 1 prostate cancer: a retrospective cohort with long-term follow-up.

Motivations and experiences of high-risk men in risk-adapted prostate cancer early detection: A qualitative study.

European Society of Urogenital Radiology (ESUR) perspectives on the role of prostate MRI in active surveillance.

Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancers.

Splicing factor TRA2B enhances synthesis of androgen receptor variant AR-V7 in prostate cancer cells.

The impact of prostate size on single-port robot-assisted radical prostatectomy surgical outcomes.

Radiopharmaceutical Therapy in Oncology: Perspectives from Transatlantic Experts.

A single-cell and spatial atlas of prostate cancer reveals the combinatorial nature of gene modules underlying lineage plasticity and metastasis.

Unveiling the Clinical Potential of Prostate Cancer Three-dimensional Models: A Systematic Review.

Dosimetry Analysis of 177Lu-PSMA-I&T in Patients with Low-Volume Oligometastatic Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the LUNAR Trial.

[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study.

[177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study.

Diagnostic assessment of artificial intelligence reconstruction on accelerated prostate MRI: a retrospective, paired, multi-reader multi-case study.

Cytoplasmic versus nuclear localization of androgen receptor splice variant 7 as a predictor of benefit from androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer (PROPHECY trial).

First-in-Human Combination of Lead-212-Labeled PSMA Radioligand Therapy and Metabotropic Glutamate Receptor Inhibitor Riluzole as Radiosensitizer in Metastatic Castration-resistant Prostate Cancer.

Consensus Recommendations for Disease- and Treatment-Related Fatigue in Patients With Advanced Prostate Cancer: A Modified Delphi Panel.

Patterns and Predictors of Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Detected Local Recurrence Following Postprostatectomy Salvage Radiotherapy for Prostate Cancer.

Optimal management of oligometastatic prostate cancer: current state and future directions.

A Two-Factor Bedside Prognostic Score Integrating Eastern Cooperative Oncology Group (ECOG) Performance Status and Aggressive Metastatic Burden in Metastatic Hormone-Sensitive Prostate Cancer.

Upper Tract Tumors

Temporal trends and predictors of inpatient palliative care in metastatic upper urinary tract carcinoma: An observational study.

Stage-Specific Prognostic Impact of Tumor Location in Upper Tract Urothelial Carcinoma: A Propensity Score-Matched Analysis.

TROP2 Expression Is Associated with Early Stage and Favorable Prognosis in Upper Tract Urothelial Carcinoma - Beyond the Abstract

Endoscopic Kidney-Sparing Surgery Outcomes of High-Grade Upper Tract Urothelial Cancer - Beyond the Abstract

Upper tract urothelial carcinoma associated with Lynch syndrome.

Testicular Cancer

Testicular Cancer: Diagnosis, Treatment, and Biomarker Advances.

Overlapping genetic etiology of pediatric and adult germ cell tumors.

Comparison of Perioperative and Oncologic Outcomes Between Robotic and Open Retroperitoneal Lymph Node Dissection in Testicular Cancer: A Systematic Review and Meta-analysis.

Postchemotherapy orchiectomy in metastatic testicular germ cell tumors: Pathologic findings and predictors of residual viable disease.

The Functional Role and Molecular Characterization of the Therapeutic Target CLDN6 in Germ Cell Tumors.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC